Cardiomyopathy Associated with Anti-SARS-CoV-2 Vaccination: What Do We Know?
The SARS-CoV-2 pandemic has mobilized many efforts worldwide to curb its impact on morbidity and mortality. Vaccination of the general population has resulted in the administration of more than 6,700,000,000 doses by the end of October 2021, which is the most effective method to prevent hospitalizat...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-12-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/13/12/2493 |
| _version_ | 1827669023970557952 |
|---|---|
| author | Alfredo Parra-Lucares Luis Toro Sebastián Weitz-Muñoz Cristóbal Ramos |
| author_facet | Alfredo Parra-Lucares Luis Toro Sebastián Weitz-Muñoz Cristóbal Ramos |
| author_sort | Alfredo Parra-Lucares |
| collection | DOAJ |
| description | The SARS-CoV-2 pandemic has mobilized many efforts worldwide to curb its impact on morbidity and mortality. Vaccination of the general population has resulted in the administration of more than 6,700,000,000 doses by the end of October 2021, which is the most effective method to prevent hospitalization and death. Among the adverse effects described, myocarditis and pericarditis are low-frequency events (less than 10 per 100,000 people), mainly observed with messenger RNA vaccines. The mechanisms responsible for these effects have not been specified, considering an exacerbated and uncontrolled immune response and an autoimmune response against specific cardiomyocyte proteins. This greater immunogenicity and reactogenicity is clinically manifested in a differential manner in pediatric patients, adults, and the elderly, determining specific characteristics of its presentation for each age group. It generally develops as a condition of mild to moderate severity, whose symptoms and imaging findings are self-limited, resolving favorably in days to weeks and, exceptionally, reporting deaths associated with this complication. The short- and medium-term prognosis is favorable, highlighting the lack of data on long-term evolution, which should be determined in longer follow-ups. |
| first_indexed | 2024-03-10T03:54:43Z |
| format | Article |
| id | doaj.art-ff2423a5d7ba43d39da7e2b72f35a165 |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-03-10T03:54:43Z |
| publishDate | 2021-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-ff2423a5d7ba43d39da7e2b72f35a1652023-11-23T10:58:42ZengMDPI AGViruses1999-49152021-12-011312249310.3390/v13122493Cardiomyopathy Associated with Anti-SARS-CoV-2 Vaccination: What Do We Know?Alfredo Parra-Lucares0Luis Toro1Sebastián Weitz-Muñoz2Cristóbal Ramos3Division of Critical Care Medicine, Department of Medicine, Hospital Clínico Universidad de Chile, Santiago 8380420, ChileDivision of Nephrology, Department of Medicine, Hospital Clínico Universidad de Chile, Santiago 8380420, ChileDivision of Internal Medicine, Department of Medicine, Hospital Clínico Universidad de Chile, Santiago 8380420, ChileDepartment of Radiology, Hospital Clínico Universidad de Chile, Santiago 8380420, ChileThe SARS-CoV-2 pandemic has mobilized many efforts worldwide to curb its impact on morbidity and mortality. Vaccination of the general population has resulted in the administration of more than 6,700,000,000 doses by the end of October 2021, which is the most effective method to prevent hospitalization and death. Among the adverse effects described, myocarditis and pericarditis are low-frequency events (less than 10 per 100,000 people), mainly observed with messenger RNA vaccines. The mechanisms responsible for these effects have not been specified, considering an exacerbated and uncontrolled immune response and an autoimmune response against specific cardiomyocyte proteins. This greater immunogenicity and reactogenicity is clinically manifested in a differential manner in pediatric patients, adults, and the elderly, determining specific characteristics of its presentation for each age group. It generally develops as a condition of mild to moderate severity, whose symptoms and imaging findings are self-limited, resolving favorably in days to weeks and, exceptionally, reporting deaths associated with this complication. The short- and medium-term prognosis is favorable, highlighting the lack of data on long-term evolution, which should be determined in longer follow-ups.https://www.mdpi.com/1999-4915/13/12/2493myocarditispericarditisvaccinesCOVID-19SARS-CoV-2epidemiology |
| spellingShingle | Alfredo Parra-Lucares Luis Toro Sebastián Weitz-Muñoz Cristóbal Ramos Cardiomyopathy Associated with Anti-SARS-CoV-2 Vaccination: What Do We Know? Viruses myocarditis pericarditis vaccines COVID-19 SARS-CoV-2 epidemiology |
| title | Cardiomyopathy Associated with Anti-SARS-CoV-2 Vaccination: What Do We Know? |
| title_full | Cardiomyopathy Associated with Anti-SARS-CoV-2 Vaccination: What Do We Know? |
| title_fullStr | Cardiomyopathy Associated with Anti-SARS-CoV-2 Vaccination: What Do We Know? |
| title_full_unstemmed | Cardiomyopathy Associated with Anti-SARS-CoV-2 Vaccination: What Do We Know? |
| title_short | Cardiomyopathy Associated with Anti-SARS-CoV-2 Vaccination: What Do We Know? |
| title_sort | cardiomyopathy associated with anti sars cov 2 vaccination what do we know |
| topic | myocarditis pericarditis vaccines COVID-19 SARS-CoV-2 epidemiology |
| url | https://www.mdpi.com/1999-4915/13/12/2493 |
| work_keys_str_mv | AT alfredoparralucares cardiomyopathyassociatedwithantisarscov2vaccinationwhatdoweknow AT luistoro cardiomyopathyassociatedwithantisarscov2vaccinationwhatdoweknow AT sebastianweitzmunoz cardiomyopathyassociatedwithantisarscov2vaccinationwhatdoweknow AT cristobalramos cardiomyopathyassociatedwithantisarscov2vaccinationwhatdoweknow |